BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7607381)

  • 1. [Immunohistochemical detection and prognostic significance of p53 in the primary tumor of breast carcinoma patients].
    Beck T; Weller E; Weikel W; Brumm C; Wilkens C; Knapstein PG
    Geburtshilfe Frauenheilkd; 1995 May; 55(5):252-7. PubMed ID: 7607381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
    Beck T; Weller EE; Weikel W; Brumm C; Wilkens C; Knapstein PG
    Gynecol Oncol; 1995 Apr; 57(1):96-104. PubMed ID: 7705708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
    Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
    Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
    Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
    Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
    Temmim L; Baker H; Sinowatz F
    Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of neu-protein for prognosis of breast cancers].
    Mitze M; Beck T; Weikel W; Rosenthal H; Knapstein PG
    Geburtshilfe Frauenheilkd; 1990 Oct; 50(10):771-6. PubMed ID: 1981044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.
    Nakopoulou LL; Alexiadou A; Theodoropoulos GE; Lazaris AC; Tzonou A; Keramopoulos A
    J Pathol; 1996 May; 179(1):31-8. PubMed ID: 8691341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival.
    Hanzal E; Gitsch G; Kohlberger P; Dadak C; Miechowiecka N; Breitenecker G
    Anticancer Res; 1992; 12(6B):2325-9. PubMed ID: 1295480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
    Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
    Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
    Rudland PS; Platt-Higgins A; El-Tanani M; De Silva Rudland S; Barraclough R; Winstanley JH; Howitt R; West CR
    Cancer Res; 2002 Jun; 62(12):3417-27. PubMed ID: 12067984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunohistochemical analysis of p53 and c-erbB-2 in breast cancer].
    Castiglioni T; Elsner B; Curutchet HP; Montesinos M; Debonis D
    Medicina (B Aires); 1995; 55(5 Pt 1):415-20. PubMed ID: 8728771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor expression in male breast carcinoma: lack of clinicopathological association.
    Pich A; Margaria E; Chiusa L; Candelaresi G; Dal Canton O
    Br J Cancer; 1999 Feb; 79(5-6):959-64. PubMed ID: 10070897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
    McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
    Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up.
    Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
    Clin Cancer Res; 2003 Feb; 9(2):716-21. PubMed ID: 12576440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.